Association of HCV genotype with viral load among Iranian blood donors: a penalized logistic regression

Fahimeh Ranjbar Kermani1, Sedigheh Amini Kafi-Abad*,1, Kamran Mousavi Hosseini1, Mahtab Maghsudlu1, Zohreh Sharifi3, Mohammad Ali Mansournia2

Received: 13 Feb 2019                           Published: 24 Dec 2019

Abstract

Background: Hepatitis C virus (HCV) is a blood borne virus and the leading cause of advanced hepatitis disease. HCV genotype 3a is predominant among Iranian blood donors. The aim of this study was to evaluate the relationship between HCV genotype and HCV viral load.

Methods: In this analytical cross-sectional study 106 anti-HCV positive and HCV RNA positive blood donors referred to Iranian blood centers across the county were entered. HCV viral loads were determined by an in-house one step Taq Man Real-Time RT-PCR assay. Penalized logistic regression was performed for data analysis. STATA software version 13 was used for statistical analysis.

Results: The mean age was 37.94 ± 9.04 years ranged from 19 to 58 years. Male gender included 104 (98.1%) of subjects. 31, 10 and 65 subjects were infected with genotypes 1a, 1b, and 3a, respectively. The mean viral load was 1.44 × 10^6 ± 4.5 × 10^5 IU/ml. HCV viral load was not significantly different among subjects infected with HCV genotypes 1, 1.49 × 10^6 ± 4.57 × 10^6 IU/ml compare to genotype 3, 1.40 × 10^6 ± 5.58 × 10^6 IU/ml (p=0.93).

Conclusion: Although not significant, the frequency of subjects with high viral load (> 800,000 IU/ml) was higher in subjects infected with genotype 3 than those of genotype 1. No associations were found between demographic characteristics and HCV genotype. Although the study was unable to find any association between HCV genotype and HCV viral load/ HCV viral load group, it highlighted the role of high viral load in the high circulation of HCV genotype 3a among Iranian blood donors.

Keywords: Blood donors, Hepatitis C, Viral load, Genotype, sequencing, Iran

Introduction

Hepatitis C virus (HCV) is a major health problem worldwide. HCV is one of the leading causes of acute and chronic liver diseases, the severity of which can range from a mild illness to a lifelong disease. The majority of patients are asymptomatic and unaware of their infection (1). HCV is a blood-borne virus, and exposure to blood is the most common mode of HCV transmission. Annually, 399,000 persons die of hepatitis C due to cirrhosis and hepatocellular carcinoma. It is estimated that 71 million people are living with chronic HCV infection worldwide.

*What is “already known” in this topic:
HCV is classified into seven major genotypes. Some studies have shown that HCV viral load in patients infected with HCV genotype 2 or 3 is lower than those infected with HCV genotype 1. Other studies have reported an association between high viral load and genotype 3. The association was not clarified among Iranian blood donors.

—What this article adds:
Although we were unable to find any association between HCV genotype and HCV viral load, we highlighted the role of high viral load in the high circulation of HCV genotype 3a among Iranian blood donors.
The prevalence of chronic HCV varies in different regions, and according to the World Health Organization (WHO), Eastern Mediterranean (2.3%) and European (1.5%) countries are the most affected regions, and the prevalence of this infection ranges from 0.5% to 1% in other WHO regions (2, 3). In Iran, the overall rate of HCV viremia is 0.4% (4).

HCV is a small, enveloped, positive-stranded RNA virus. HCV genome encodes a polyprotein of approximately 3000 amino acids in length. This polyprotein is posttranslationally cleaved to structural and nonstructural proteins (5). Due to the high genetic heterogeneity of HCV genome and based on phylogenetic analysis, up to now, HCV has been classified into seven major genotypes, which includes many subtypes. HCV genotypes/subtypes are region-specific. A very recent study showed that HCV genotype 3 (subtype 3a) is the most frequent one followed by genotype 1 (1a and 1b) and revealed changes in molecular epidemiology of HCV from the previously most common genotype 1 to the currently most frequent genotype 3 among Iranian blood donors (8).

With the improvement of molecular methods, HCV RNA quantification has become possible. Both HCV genotyping and viral load testing are important for the management of HCV infection (9). It is suggested that HCV genotype is related to viral load, and specific HCV genotype affects HCV RNA level. Controversy exists over the relationship between HCV genotype and HCV viral load. Studies have shown that HCV viral load is significantly higher in patients infected with genotype 1 than those infected with genotype 2 or 3 (10-15). However, some other studies failed to find any significant association in this regard (16, 17). On the other hand, based on a cut-off value of approximately 6 log _10_ IU/ml (800,000 IU/ml or 1000,000 IU/ml according to former studies), some studies have reported an association between high viral load and genotype 3, though in some studies, this association was not significant (17-21).

Given the discrepancy regarding the link between HCV genotype and viral load and the predominance of HCV genotype 3a among Iranian blood donors, we sought to evaluate the relationship between HCV genotype and HCV viral load.

**Methods**

**Study population**

This analytical cross-sectional study was performed on HCV RNA-positive blood donors referred to the Iranian blood transfusion centers over the country during 2015-2017 (22). The subjects were positive in anti-HCV confirmation tests and did not have positive results in screening tests of HBV, HIV, and in seven provinces of Iran performing human T-lymphotropic virus (HTLV) screening test, they also did not have positive results in HTLV testing. A total of 9 ml of whole blood was collected from the subjects in vacutainer tubes, and the samples were immediately centrifuged at 3000 rounds per minute (RPM) for 10 min and stored at -70°C until further processing. A partial sequence of non-structural 5b (NS5b) region of HCV genome was already amplified and sequenced for determining HCV genotypes in all the samples in the previous study of the authors (8). All the blood donors whose HCV genotype was determined were included in this study.

Therefore, 106 subjects with identified HCV genotype were subjected to HCV RNA quantification.

**RNA extraction and viral load determination**

TriPure Isolation Reagent (Roche, Germany) was used for RNA extraction according to the instruction of manufacturer. Eluted HCV RNA in 20 µL elusion buffer was used for HCV viral load testing. HCV viral loads were determined by an in-house one-step TaqMan Real-Time RT-PCR assay using LightCycler instrument (Roche, Germany) to amplify a segment of non-coding region (NCR) of HCV genome that is described elsewhere (23). Briefly, 2 µl of each extracted RNA sample and 18 µl of one-step TaqMan Real-Time RT-PCR Master Mix were mixed in individual capillaries. The following program of thermal cycling was performed: 50°C for 15 min, 94°C for 10 min, followed by 45 cycles of 95°C for 5 s, 60 cycles for 20 s, and 72°C for 10 s followed by a cycle of 40°C for 30 s. Four HCV RNA quantification standards (QS) of the artus HCV LC RT-PCR reagent (Qiagen, Hamburg GmbH, Germany) were used, and all standards were calibrated against the world health organization (WHO) international HCV RNA standard. The lower and upper detection limits of the in-house one-step TaqMan Real-Time RT-PCR assay were 8 × 10^1 IU/L and 8 × 10^6 IU/L.

**Statistical analysis**

Descriptive data were expressed as mean ± standard deviation (SD) or percentages (%). HCV RNA levels were grouped based on the cut-off value of 800,000 IU/ml: ≤ 800,000 IU/ml indicated low viral load and > 800,000 IU/ml signified high viral load (20, 24, 25). Based on 10-year intervals, the subjects were grouped as 19-28, 29-38, 39-48, and 49-58 years old. T-test and analysis of variance (ANOVA) were applied for comparison of HCV viral load according to gender, age group, and genotype. Penalized logistic regression model via data augmentation using the prior log-F (2, 2) was performed to deal with sparse data bias for analyzing the association between HCV viral load groups and age groups, gender, and HCV genotype (26-28), and the results were summarized as odds ratio (OR) with 95% confidence interval (CI). Alpha level of 0.05 was considered as the significance level. Statistical analyses were performed using STATA software (STATA 13 Corp., College Station, Texas).

**Ethical Statement**

The Ethics Committee of High Institute for Research and Education in Transfusion Medicine, Tehran, Iran, approved the study (code No: IR.TMI.REC.1394.1800).
Results

During the study period, 106 subjects were included. Out of the 106 blood donors, 65 (61.32%±9.6%) were infected with genotype 3 (subtype 3a), and 41 (38.68) were infected with genotype 1, 31 with subtype 1a (29.25%±9.0) and 10 with subtype 1b (9.43%±6.05). The mean age of the subjects was 37.94±9.04 years (age range: 19-58 years), and the median was 37 years. Most donors were male (98.1% of subjects), and 2 were female. The mean viral load was $1.44 \times 10^6 \pm 4.5 \times 10^5$ IU/ml (range: from $2.28 \times 10^3$ to $3.42 \times 10^7$ IU/ml). The majority of the subjects (74.53%) fell in the low viral load group (Table 1).

As shown in Table 2, no significant relationship was found between mean viral load in donors infected with HCV and age group, gender, genotypes, and subtypes ($p=0.639, 0.686, 0.931,$ and $0.640$, respectively).

The rates of different viral load groups based on age group, gender, and genotype and the relevant ORs with 95% CIs for penalized logistic regression model predicting high viral load are shown in Table 3. No association was found between viral load groups and age (OR: $1.03\pm0.03$, 95% CI 0.98-1.08, $p=0.204$). Among all the age groups, blood donors with high HCV viral loads had lower frequencies than those with low viral loads, this rate was the highest in the 48-59 age group, though the relationship was not significant. Two (100%) female patients and the majority of the male subjects (74.04%) had low viral loads, but the association was not significant (OR: $1.89\pm0.25$, 95% CI 0.1-19.38, $p=0.59$). Insignificantly, the frequency of patients with high viral loads (> $800,000$ IU/ml) in subjects infected with genotype 3 was higher than that of genotype 1 (26.15% vs. 24.39%; OR: $1.09\pm0.48$, 95% CI 0.46 - 2.57, $p=0.85$) (Table 3).

Discussion

The association between HCV genotype and HCV viral load has been widely studied, and the results are conflicting. A significant association was reported by some studies, while some others failed to find any significant relationships. In the present study, the real-time technique was used for the quantification of HCV RNA among well-defined HCV genotype blood donors. Although the mean viral load in donors infected with HCV genotype 1a was

| Factor                          | Value                  | OR (95% CI)   |
|---------------------------------|------------------------|---------------|
| Age groups (years)              |                         |               |
| 19-28                           | 12 (75)                | 4 (25)        |
| 29-38                           | 33 (80.49)             | 8 (19.51)     |
| 39-48                           | 24 (72.73)             | 9 (27.27)     |
| 49-58                           | 8 (57.14)              | 6 (42.86)     |
| Gender, N (%)                   |                         |               |
| Male                            | 77 (74.04)             | 27 (25.96)    |
| Female                          | 2 (100)                | 0 (0)         |
| HCV genotype                    |                         |               |
| 1                               | 33 (80.49)             | 8 (19.51)     |
| 3                               | 49 (75.38)             | 16 (24.62)    |

*Odds ratio, **Confident interval, †2 missing values, HCV: hepatitis C virus
HCV viral load in relation to HCV genotype

higher than in those with the other two genotypes, no significant association was found in this regard. This result is in line with the findings of a study reported from central regions of Iran that was conducted on 191 patients (16). Nishiya et al. revealed that the mean viral load of blood donors infected with HCV genotype 1a was higher than that of patients infected with HCV genotype 3a (29). Rong et al. reported that blood donors infected with HCV genotypes 1 and 6 are more likely to have higher viral loads than those infected with other genotypes (15). Generally, the association between higher mean viral load and genotype 1 was revealed in various populations in different geographical regions (10-14). Those studies confirmed higher efficiency of viral replication in genotype 1 compared to other genotypes.

In this study, based on the cut-off value of 800,000 IU/ml, HCV viral loads were categorized into low and high viral load. The frequency of subjects with high viral load was higher in genotype 3 than genotype 1, although the association was not significant (Table 3). The distribution of HCV genotype was comparable among subjects with viral load ≥ 800,000 IU/ml and total subjects. HCV genotype 3 was more frequent than genotype 1 in both groups (66.67% vs. 33.33% in the former and 61.32% vs. 38.68% in the latter). This finding may clarify the role of high viral load in changes in the molecular epidemiology of HCV among Iranian blood donors and the replacement of previously dominant genotype 1a with the recently dominant genotype 3 (subtype 3a) over the years (8, 30).

An Iranian study conducted by Hajia et al. reported that subtype 1a was the most prevalent subtype among all study subjects, and this subtype had the highest rate among the subjects with viral loads higher than 800,000 IU/ml (20). Studies in Pakistan showed that genotype 3 was the most frequent among total patients, and most patients with high viral loads (> 800,000 IU/ml) were infected with genotype 3, and the relation was significant (18, 19). In contrast, other studies in Pakistan reported genotype 3 was the most frequent genotype, but genotype 3 was not the one with the highest frequency among patients with high viral loads (17, 31). In a recent review by Zhang et al., a significant association was found between high viral load (≥ 10^6 IU/ml) and genotypes 1b and 6a that are frequent genotypes in Korea (21). The positive association between HCV viral load and virus transmission rate has been reported in vertical and percutaneous exposure (32, 33).

Although with recent improvements of direct-acting agents (DAAs), the response rate of all genotypes are comparable, and treatment of patients infected with HCV genotype 3 remains a challenging issue. In addition, the response rate of patients with genotype 3 is lower than those with other genotypes (34).

Studies have indicated that hepatic steatosis is an independent factor for the severity and progression of liver diseases in chronic HCV patients (35). Steatosis is more likely to be associated with viral factors such as viral load than host factors in genotype 3 infected patients compared to other genotypes (34, 36). In the current study, the frequency of blood donors with viral load > 800,000 IU/ml was higher in blood donors infected with genotype 3 (26.15%) compared to those with genotype 1 (24.39%). Our finding is in agreement with the instruction of new DAAs available in Iran, which stated that cirrhosis patients infected with genotype 3 are difficult cases to treat and need more strengthened therapy and longer treatment duration (37). However, other studies discussed the role of HCV genotype 1a or other factors on a sustained virological response (SVR) to pegIFN-α/RVB therapy among chronic HCV patients (38, 39).

However, a very recent report of a clinical trial in Iran showed an excellent response rate of newly available DAAs in Iranian cases infected with both genotypes 1 and 3 and demonstrated that genotype 3 is no longer difficult to treat (40).

In contrast to some part of Iran that HCV genotype 1b was the dominant genotype (41), in the present study, the prevalence of HCV genotype 1b was the lowest among Iranian blood donors (9.43%±6.05) and subjects with genotype 1b were not included in statistical analysis, separately. In our study, the low sample size was the limitation. Although we used a penalized conditional logistic regression model in data analysis to control some statistical bias in the association between HCV genotype and HCV viral load, possibly due to limited sample size, no statistical significance was found in the regression model.

**Conclusion**

Although no significant association between HCV genotype and HCV viral load or HCV viral load groups was found, it seems that the frequency of blood donors with high viral loads is higher among blood donors infected with HCV genotype 3 (genotype 3a) than those infected with genotype 1, which may have resulted in high circulation of genotype 3a among Iranian blood donors. This finding is likely to give us insight into HCV transmission, particularly HCV genotype 3a as the most frequent genotype among Iranian blood donors, and may provide information on the treatment of HCV infected patients, especially those infected with genotype 3a. Further studies are needed to verify the findings of this study.

**Acknowledgments**

The authors thank our colleagues in blood transfusion centers across the country for data and sample collection. Also, the authors thank all colleagues for their technical help at the Diagnostic Laboratory of Iranian Blood Transfusion Organization, Tehran, Iran.

**Approval of the study protocol**

The Ethics Committee of High Institute for Research and Education in Transfusion Medicine, Tehran, Iran, approved the study (code No: IR.TML.REC.1394.1800).

**Conflict of Interests**

The authors declare that they have no competing interests.
References

1. Lanni S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016;22(10):1831-8.

2. Organization WH. Hepatitis C Fact Sheet, update April 2017. Geneva: World Health Organization. www.who.int/mediacentre/factsheets/fs204/en/.Accessed; 2017.

3. Organization WH. Global hepatitis report 2017: World Health Organization, 2017.

4. Mirminachi B, Mohammadzadeh A, Maniati M, B. Mohammadi Z, Merat S, Neishabouri A, Sharifi AH, Alavian SH, et al. Update on the Prevalence of Hepatitis C Virus Infection Among Iranian General Population: A Systematic Review and Meta-Analisis. Hepat Mon. 2017;17(2).

5. Gu M, Rice CM. Structures of hepatitis C virus nonstructural proteins required for replicase assembly and function. Curr Opin Virol. 2013;3(2):129-36.

6. Simmonds P, Becher P, Buhk J, Gould EA, Meyers G, Monath T, et al. ICTV Virus Taxonomy Profile: Flaviviridae. J Gen Virol. 2017;98(1):2-3.

7. Smith DB, Buhk J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 46 subtypes: updated criteria and genotype assignment work resource. Hepatology. 2014;59(1):318-27.

8. Kermani FR, Amini-K hashad S, Hosseini KM, Maghsoudlu M, Sharifi Z, Afshari R. Iran. Hepatitis C Virus Genotypes and Related Risk Factors Among Iranian Blood Donors: A Penalized Logistic Regression. Jundishapur J Microbiol. 2018;11(12).

9. Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Thadani U, et al. Expanded classification of hepatitis C virus into 7 genotypes and 46 subtypes: an update. Clin Microbiol Infect. 2012;18(4):369-75.

10. Merat S, Sharifi AH, Haj-Sheykholeslami A, Poustchi H, Fatthi B, et al. Hepatitis C genotypes and viral loads in chronic hepatitis C infected patients of Hazara Pakistan. Virol J. 2011;8(1):466.

11. Chakravarti A, Dogra G, Verma V, Srivastava AP. Distribution of Hepatitis C Virus Genotypes and related risk factors among the carrier child patients. J Med Virol. 2011;83(1):90-5.

12. Doostan F, Jahanshahi MJ, Hassanzadeh F, Bazzafshani M. The Relationship between Hepatitis C Genotypes and Viral Load: a study on hepatitis C patients in Kerman, Iran using Real-time PCR. Journal of Kerman University of Medical Sciences. 2017;24(2):159-65.

13. Petruzziello A, Coppola N, Loquercio G, Marigliano S, Giordano M, et al. Determination of HCV genotypes and viral loads in chronic HCV infected patients of Okara and Toba Tek Singh Districts of Punjab, Pakistan. Virol J. 2014;11(1):24.

14. Afridi SQ, Khan N, Ali S, Attaullah S, Bahadar S, et al. Distribution pattern of hepatitis C virus genotypes and related risk factors in chronic positive patients. Intervirology. 2010;53(6):311-8.

15. Soriano V, Moorcroft A, Rockstroh J, Ledergerber B, Knyz B, Chaplinskas S, et al. Spontaneous viral clearance, viral load, and correlation with viral load and risk factors in chronic positive patients. J Inf Dis. 2008;198(3):437-44.

16. Riaz S, Bashir MF, Haider S, Rahid N. Association of genotypes with viral load and biochemical markers in HCV-infected Sindhi patients. J Viral Hepat. 2013;20(2):77-84.

17. Zhang Y, Chen LM, He M. Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution. Virol J. 2017;14(1):41.

18. Ranjbar Kermani F, Moussavi Hosseini K, Amini Kafi-Abad S, Mansournia M, Sharifi Z, Maghsoudlu M. Hepatitis C (HCV) viremia rate and its correlation to demographic factors among HCV confirmed Iranian blood donors. Arch Iran Med. 2019;22(2):76-79.

19. Kermani FR, Kafi-Abad S, Hosseini KM, Maghsoudlu M, Sharifi Z, Samice S. Evaluation of the Performance Characteristics of an In-House One Step TaqMan Real Time-Polymerase Chain Reaction Assay for Detection and Quantification of Hepatitis C Virus. Jundishapur J Microbiol. 2017;10(3).

20. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74.

21. JM P. Hepatitis C 101: What Does Viral Load Mean? https://hepaticst.net/answers/what-does-viral-load-mean-2015.

22. Greenwood S, Mansournia MA. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2017;23(12):1345-e54.

23. Greenwood S, Mansournia MA, Altman DG. Sparse data bias: a problem in hiding in plain sight. BMJ. 2016;352:i1981.

24. Mansournia MA, Geroldinger A, Greenwood S, Heinze G. Separation in Logistic Regression – Causes, Consequences, and Control. Am J Epidemiol. 2017;2016 Apr 27;352:i1981.

25. Nishiya AS, de Almeida-Neto C, Ferreira SC, Alencar CS, Di-Lorenzo-Oliveira C, Levi JE, et al. HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in Sao Paulo, Brazil. PLoS One. 2014(9(1):e86413.

26. Mahmud S, Al-Kanaani Z, Chemaitelly H, Chaabna K, Koyoumjanian SP, Abu-Raddad LJ. Hepatitis C virus genotypes in the Middle East and North Africa: Distribution, diversity, and patterns. J Med Virol. 2018;90(1):131-41.

27. Riaz S, Bashaer MF, Haider S, Rahid N. Association of genotypes with viral load and biochemical markers in HCV-infected Sindhi patients. J Viral Hepat. 2013;20(2):77-84.

28. Chan A, Patel K, Naggie S. Genotype 3 Infection: The last stand of hepatitis C virus. Drugs. 2017;77(2):131-44.

29. Alavian SM, Sharafi H, Mirshamsi M, Vazirizadeh A, Omranipour R, Fakhri A, et al. Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017. Hepat Mon. 2017 November; 17(11):e69356.

30. Fateh A, Aghashehdeghi MR, Keyvani H, Mollaie HR, Yari S, Hadizade Tasbiri AR. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment. Asian Pac J Cancer Prev. 2015; 16:1873-1880.

31. Sadeghi F, Bokharaei-Salim F, Salehi-Vaziri M, Monavari SH, Alavian SM, Salimi S, et al. Associations between human TRIM22 gene expression and the response to combination therapy with Peg IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C: A Med Virol. 2014;86(9):949-506.

32. Merat S, Sharifi AH, Haji-Sheykholeslami A, Poustchi F, Fatthi B, Nagehi-Baygi A, et al. The efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3. J Hepatol. 2017;17(1).

33. Bokharaei-Salim F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Nasseri S. Distribution of hepatitis C virus genotypes among azerbaijani patients in capital city of Iran-tehran. Hepat Mon. 2013;3(1):9.

F. Ranjbar Kermani, et al.